<DOC>
	<DOCNO>NCT00963885</DOCNO>
	<brief_summary>This 2 part study evaluate efficacy safety 12 24 week treatment RO5190591 ( danoprevir ) combination Pegasys Copegus , compare Pegasys Copegus alone , treatment-naive patient chronic hepatitis C genotype 1 virus infection.In Part 1 study , patient randomize receive either 1 ) RO5190591 300mg po every 8 hour , 2 ) RO5190591 600mg po every 12 hour , 3 ) RO5190591 900mg po every 12 hour 4 ) placebo , combination standard dose Pegasys Copegus . If safety virological response data Part 1 study supportive , Part 2 patient randomize receive either 1 ) RO5190591 300mg po every 8 hour 600mg po every 12 hour 900mg po every 12 hour 2 ) placebo , combination standard dose Pegasys Copegus . The anticipated time study treatment 24-48 week , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study RO5190591 ( Danoprevir ) Combination With Pegasys Copegus Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic hepatitis C , genotype 1 ; treatmentnaive . liver cirrhosis form liver disease ; HIV infection ; hepatocellular cancer ; cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>